Materias dentro de su búsqueda.
Materias dentro de su búsqueda.
Historia
24
Películas cinematográficas
16
Música popular
13
Novela estadounidense
12
Jazz
10
Música para órgano
7
Crítica e interpretación
6
Música rock
6
Correspondencia
5
Comedy films
4
Condiciones sociales
4
Diarios íntimos
4
Estados Unidos
4
Música
4
Música vocal (Jazz)
4
Novelistas ingleses
4
Arte
3
Aspectos sociales
3
Bailarines
3
Blues (Música)
3
Christmas music
3
Foreign films
3
Historia y crítica
3
Libros falsos
3
Literatura estadounidense
3
Motetes
3
Música de jazz
3
Operas
3
Songs (High voice) with piano
3
Songs (Medium voice) with piano
3
-
2001por Saber, Mostafa M, El Zawahry, Heba M, Hilal, Amany M, Abou-Bakr, Amany A, Namour, Alfred E, Saber, Mona M“…CONCLUSION: High TILs is good prognosis in HER2 enriched breast cancer provided that patients received HER2 directed therapy. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2002por Grela-Wojewoda, Aleksandra, Püsküllüoğlu, Mirosława, Sas-Korczyńska, Beata, Zemełka, Tomasz, Pacholczak-Madej, Renata, Wysocki, Wojciech M., Wojewoda, Tomasz, Adamczyk, Agnieszka, Lompart, Joanna, Korman, Michał, Mucha-Małecka, Anna, Ziobro, Marek, Konduracka, Ewa“…SIMPLE SUMMARY: Trastuzumab administered as a (neo)adjuvant therapy in radically treated Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer patients improves overall survival. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2003“…Cell-membrane cellular subfractions of SKBR3/HER2+ breast cancer cells, used as a model system, were analyzed by high resolution mass spectrometry, and high-quality proteins (FDR<3%) identified by at least two unique peptides were mapped to the cancer hallmark database. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2004por Hu, Jin, Zhang, Yanting, Dong, Fang, Shen, Jian, Chen, Hengyu, Li, Lei, Huang, Tao“…BACKGROUND: The role of human epidermal growth factor receptor 2 (HER2) in metaplastic breast cancer (MBC) patients remains unclear. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2005por Lambertini, Matteo, Fielding, Shona, Loibl, Sibylle, Janni, Wolfgang, Clark, Emma, Franzoi, Maria Alice, Fumagalli, Debora, Caballero, Carmela, Arecco, Luca, Salomoni, Sharon, Ponde, Noam F, Poggio, Francesca, Kim, Hee Jeong, Villarreal-Garza, Cynthia, Pagani, Olivia, Paluch-Shimon, Shani, Ballestrero, Alberto, Del Mastro, Lucia, Piccart, Martine, Bines, Jose, Partridge, Ann H, de Azambuja, Evandro“…Limited data with short follow-up exist on the prognostic value of age at diagnosis in HER2-positive BC and the benefit of anti-HER2 therapy in young patients. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2006por Kim, Yong-Seok, Sun, Der Sheng, Ahn, Juneyoung, Kim, Yongseon, Yoon, Jung-Sook, Won, Hye Sung“…SIMPLE SUMMARY: This study provides information about the genetic alterations associated with disease recurrence in early stage HER2-positive breast cancer. We found seven upregulated and two downregulated differentially expressed genes in patients with recurrence. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2007por Kalra, Rashi, Chen, Ching Hui, Wang, Junkai, Salam, Ahmad Bin, Dobrolecki, Lacey E., Lewis, Alaina, Sallas, Christina, Yates, Clayton C., Gutierrez, Carolina, Karanam, Balasubramanyam, Anurag, Meenakshi, Lim, Bora, Ellis, Matthew J., Kavuri, Shyam M.“…The pan-HER tyrosine kinase inhibitor (TKI) neratinib is therapeutically active against metastatic breast cancers harboring activating HER2 mutations, but responses are variable and often not durable. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2008por Cunningham, Niamh, Shepherd, Scott, Mohammed, Kabir, Lee, Karla A., Allen, Mark, Johnston, Stephen, Kipps, Emma, McGrath, Sophie, Noble, Jillian, Parton, Marina, Ring, Alistair, Turner, Nicholas C., Okines, Alicia F. C.“…PURPOSE: To describe the tolerability and efficacy of neratinib as a monotherapy and in combination with capecitabine in advanced HER2-positive breast cancer in a real-world setting. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2009por Spring, Laura M., Han, Hyo, Liu, Minetta C., Hamilton, Erika, Irie, Hanna, Santa-Maria, Cesar A., Reeves, James, Pan, Peng, Shan, Ming, Tang, Yongqiang, Graham, Julie R., Hazard, Sebastien, Ellisen, Leif W., Isakoff, Steven J.“…This single-arm pilot study (NCT03329937) evaluated neoadjuvant niraparib antitumor activity and safety in patients with localized HER2-negative, BRCA-mutated breast cancer. Twenty-one patients received niraparib 200 mg once daily in 28-day cycles. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2010por Wang, Junbiao, Lamolinara, Alessia, Conti, Laura, Giangrossi, Mara, Cui, Lishan, Morelli, Maria Beatrice, Amantini, Consuelo, Falconi, Maurizio, Bartolacci, Caterina, Andreani, Cristina, Orlando, Fiorenza, Provinciali, Mauro, Del Pizzo, Francesco Domenico, Russo, Francesca, Belletti, Barbara, Riccardo, Federica, Bolli, Elisabetta, Quaglino, Elena, Cavallo, Federica, Amici, Augusto, Iezzi, Manuela, Marchini, Cristina“…The introduction into the clinic of the anti-HER2 monoclonal antibody trastuzumab considerably improved the overall survival and time-to-disease progression of patients with HER2-positive breast cancer. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2011por Cui, Lishan, Quagliarini, Erica, Xiao, Siyao, Giulimondi, Francesca, Renzi, Serena, Digiacomo, Luca, Caracciolo, Giulio, Wang, Junbiao, Amici, Augusto, Marchini, Cristina, Pozzi, Daniela“…Western blot analysis demonstrated that GO treatment resulted in a marked decrease in total HER-2, associated with a down-regulation of the expression and activation of protein kinase B (AKT) and extracellular signal-regulated kinase (ERK) thus indicating that GO may act as a potent HER-2 inhibitor. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2012“…Human epidermal growth factor receptor 2 (HER2) is a key pathological characteristic of gastric cancer (GC). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2013por Tang, Shasha, Liu, Wenjing, Yong, Liyun, Liu, Dongyang, Lin, Xiaoyan, Huang, Yuan, Wang, Hui, Cai, Fengfeng“…In conclusion, high expression of KRT17 predicted favorable prognosis in BC patients with higher HER2 expression. This result may indicate that KRT17 plays a different role depending on the level of HER2 expression and could serve as a promising and sensitive biomarker for the diagnosis and prognostication of HER2(high) BC.…”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2014por Shao, Bin, Liu, Xiaoran, Li, Huiping, Song, Guohong, Di, Lijun, Jiang, Hanfang, Yan, Ying, Zhang, Ruyan, Ran, Ran, Zhang, Jiayang, Liu, Yaxin, Wang, Huan, Wang, Jing“…This study aimed to examine the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) and other clinicopathological features in HER2+ MBC patients who received first-line anti-HER2 therapy. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2015por Ivanova, Mariia, Venetis, Konstantinos, Guerini-Rocco, Elena, Bottiglieri, Luca, Mastropasqua, Mauro Giuseppe, Garrone, Ornella, Fusco, Nicola, Ghidini, Michele“…SIMPLE SUMMARY: In the current clinical practice, HER2 status is tested in breast and gastroesophageal cancers to select patients eligible for anti-HER2 treatment. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2016“…CONCLUSION: Among all CDK4/6 inhibitors medications, current evidence indicated that the use of Ribociclib for HER2- negative breast cancer management was beneficial and considered to be cost-effective. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2017por Esen, Selin Aktürk, Ergun, Yakup, Erol, Cihan, Arikan, Rukiye, Er, Muhammed Muhiddin, Atci, Muhammed Mustafa, Topçu, Atakan, Uçar, Gökhan, Akagündüz, Baran, Aykan, Musa Bariş, Özen, Miraç, Baytemur, Naziyet Köse, Özçelik, Melike, Şahin, Elif, Güven, Denizcan, Menekşe, Serkan, Ak, Naziye, Teker, Fatih, Kut, Engin, Şakalar, Teoman, Alan, Özkan, Kaçan, Turgut, Turhal, Nazim Serdar, Kiliçkap, Saadettin, Türker, Sema, Şendur, Mehmet Ali Nahit, Köstek, Osman, Karaağaç, Mustafa, Sakin, Abdullah, Türk, Haci Mehmet, Çağlayan, Dilek, Cihan, Şener, Açikgöz, Yusuf, Uncu, Doğan“…Fluoropyrimidine+cisplatin/oxaliplatin+trastuzumab therapy is recommended for the first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic gastric adenocarcinoma. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2018
-
2019por Hossain, Md Shakhawat, Syeed, M. M. Mahbubul, Fatema, Kaniz, Hossain, Md Sakir, Uddin, Mohammad Faisal“…Human epidermal growth factor receptor 2 (HER2) quantification is performed routinely for all breast cancer patients to determine their suitability for HER2-targeted therapy. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2020por Wang, Zhen-hao, Zheng, Zhuo-qun, Jia, Shi−cheng, Liu, Shu-ni, Xiao, Xiao-fen, Chen, Guan-yuan, Liang, Wei-quan, Lu, Xiao-feng“…Trastuzumab is a standard molecular targeted therapy for human epidermal growth factor receptor 2(HER2) -positive breast cancer, which can significantly improve the survival of patients with this molecular subtype of breast cancer. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto